COST EFFECTIVENESS OF PEMBROLIZUMAB AND IPILIMUMAB IN ADVANCED MELANOMA

被引：3
|
作者：
Lu, T. [1 ]
Hay, J. W. [1 ]
机构：
[1] Univ Southern Calif, Los Angeles, CA USA
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 03期
关键词：
D O I：
10.1016/j.jval.2016.03.1585
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN86
引用
收藏
页码：A149 / A149
页数：1
相关论文
共 50 条
  • [31] PEMBROLIZUMAB VERSUS IPILIMUMAB FOR ADVANCED MELANOMA: FINAL OVERALL SURVIVAL ANALYSIS OF KEYNOTE-006
    Long, G.
    McNeil, C.
    Schachter, J.
    Robert, C.
    Ribas, A.
    Arance, A.
    Grob, J-J
    Mortier, L.
    Daud, A.
    Carlino, M.
    Lotem, M.
    Larkin, J.
    Lorigan, P.
    Neyns, B.
    Blank, C.
    Petrella, T. M.
    Hamid, O.
    Zhou, H.
    Ebbinghaus, S.
    Ibrahim, N.
    [J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 61 - 61
  • [32] Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006
    Blank, C.
    Lorigan, P.
    Schachter, J.
    Robert, C.
    Ribas, A.
    Long, G. V.
    Arance, A.
    Mortier, L.
    Daud, A.
    Carlino, M. S.
    McNeil, C.
    Lotem, M.
    Larkin, J.
    Neyns, B.
    Petrella, T. M.
    Hamid, O.
    Zhou, H.
    Ebbinghaus, S.
    Ibrahim, N.
    Grob, J. -J.
    [J]. MELANOMA RESEARCH, 2016, 26 : E117 - E118
  • [33] Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival analysis of KEYNOTE-006.
    Schachter, Jacob
    Ribas, Antoni
    Long, Georgina V.
    Arance, Ana
    Grob, Jean Jacques
    Mortier, Laurent
    Daud, Adil
    Carlino, Matteo S.
    McNeil, Catriona M.
    Lotem, Michal
    Larkin, James M. G.
    Lorigan, Paul
    Neyns, Bart
    Blank, Christian U.
    Petrella, Teresa M.
    Hamid, Omid
    Zhou, Honghong
    Ebbinghaus, Scot
    Ibrahim, Nageatte
    Robert, Caroline
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [34] Nivolumab and Ipilimumab in Advanced Melanoma
    Ryu, Hyewon
    Lee, Hyo Jin
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (25): : 2503 - 2503
  • [35] Ipilimumab for advanced metastatic melanoma
    Starz, Hans
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (08) : 981 - 982
  • [36] Panhypopituitarism in metastatic melanoma patient treated with ipilimumab and pembrolizumab
    Goto, Haruka
    Kasuya, Akira
    Imura, Kie
    Miyazawa, Hidehiko
    Fujiyama, Toshiharu
    Kakizawa, Keisuke
    Tokura, Yoshiki
    [J]. JOURNAL OF CUTANEOUS IMMUNOLOGY AND ALLERGY, 2019, 2 (02) : 60 - 61
  • [37] A Cost-effectiveness Analysis Comparing Pembrolizumab-Axitinib, Nivolumab-Ipilimumab, and Sunitinib for Treatment of Advanced Renal Cell Carcinoma
    Chan, Alan
    Dang, Carolyn
    Wisniewski, Jessica
    Weng, Xiuhua
    Hynson, Edward
    Zhong, Lixian
    Wilson, Leslie
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2022, 45 (02): : 66 - 73
  • [38] A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia
    Bohensky, Megan A.
    Pasupathi, Kumar
    Gorelik, Alexandra
    Kim, Hansoo
    Harrison, James P.
    Liew, Danny
    [J]. VALUE IN HEALTH, 2016, 19 (08) : 1009 - 1015
  • [39] Pembrolizumab for the treatment of advanced melanoma
    Burns, Michael C.
    O'donnell, Aidan
    Puzanov, Igor
    [J]. EXPERT OPINION ON ORPHAN DRUGS, 2016, 4 (08): : 867 - 873
  • [40] Pembrolizumab for patients with advanced melanoma
    Burki, Talha Khan
    [J]. LANCET ONCOLOGY, 2015, 16 (06): : E264 - E264
12345